Page 30 - Educacional Ponenecias Congreso SEHH-STH 2020
P. 30

5. Folsom AR, Tang W, Weng LC, Roetker NS, Cushman M, Basu S, Pankow JS. Replication of a genetic risk score for venous thromboembolism in whites but not in African Americans. J Thromb Haemost. 2016 Jan;14(1):83-8.
6. Schwartz MLB, Williams MS, Murray MF. Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance. JAMA. 2017 Apr 18;317(15):1527-8.
plex rearrangement and a retrotransposon insertion not characterized by routine diagnostic methods. bioRxiv 2020.08.28.271932; doi: https://doi. org/10.1101/2020.08.28.271932
20. De la Morena-Barrio B, Borràs N, Rodríguez-Alén A, de la Morena-Barrio ME, García-Hernández JL, Padilla J, et al. Identification of the first large intronic deletion responsible of type I antithrombin deficiency not detected by rou- tine molecular diagnostic methods. Br J Haematol. 2019 Aug;186(4):e82-
7. Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Tar-
geting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. e86.
2017 Aug 31;377(9):819-28.
8. Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, et al. Tar-
geting anticoagulant protein S to improve hemostasis in hemophilia. Blood.
2018 Mar 22;131(12):1360-71.
9. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibi-
tors. N Engl J Med. 2018 Aug 30;379(9):811-22.
10. Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, Saliba W. Factor XI
deficiency is associated with lower risk for cardiovascular and venous throm-
boembolism events. Blood. 2017 Mar 2;129(9):1210-5.
11. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al.; FXI- ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of
venous thrombosis. N Engl J Med. 2015 Jan 15;372(3):232-40.
12. DeLoughery EP, Olson SR, Puy C, McCarty OJT, Shatzel JJ. The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human
Trials. Semin Thromb Hemost. 2019 Jul;45(5):502-8.
13. Bastida JM, Benito R, González-Porras JR, Rivera J. ABCG5 and ABCG8 gene
variations associated with sitosterolemia and platelet dysfunction. Platelets.
2020 Jun 16:1-5.
14. Borràs N, García-Martínez I, Batlle J, Pérez-Rodríguez A, Parra R, et al. Un-
raveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: an Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort.Thromb Haemost. 2020 Mar;120(3):437-48.
15. Pujol-Moix N, Martínez-Pérez A, Sabater-Lleal M, Llobet D, Vilalta N, Hamsten A, et al. Influence of ABO Locus on PFA-100 Collagen-ADP Closure Time Is Not Totally Dependent on the Von Willebrand Factor. Results of a GWAS on GAIT-2 Project Phenotypes. Int J Mol Sci. 2019 Jun 30;20(13):3221.
16. Spielmann M, Lupiáñez DG, Mundlos S. Structural variation in the 3D ge- nome. Nat Rev Genet. 2018 Jul;19(7):453-67.
17. Logsdon GA, Vollger MR, Eichler EE. Long-read human genome sequencing and its applications. Nat Rev Genet. 2020;21(10):597-614.
18. Kono N, Arakawa K. Nanopore sequencing: review of potential applications in functional genomics. Dev Growth Differ. 2019 Jun;61(5):316-26.
18. de la Morena-Barrio B, Stephens J, de la Morena-Barrio ME, Stefanucci L, Padilla J, Miñano A, et al. Long-read sequencing resolves structural vari- ants in SERPINC1 causing antithrombin deficiency and identifies a com-
21. Orlando C, de la Morena-Barrio B, Pareyn I, Vanhoorelbeke K, Martínez-Mar- tínez I, Vicente V, et al. Antithrombin p.Thr147Ala, the first founder mutation from African origin responsible for inherited antithrombin deficiency Thromb Haemost. 2020 Sept 13. Online ahead of print.
22. Spreafico M, Peyvandi F. Combined FV and FVIII deficiency. Haemophilia. 2008 Nov;14(6):1201-8.
23. Dasi MA, González-Conejero R, Izquierdo S, Padilla J, García JL, García-Bar- berá N, et al. Uniparental disomy causes deficiencies of vitamin K-dependent proteins. J Thromb Haemost. 2016 Dec;14(12):2410-8.
24. De la Morena-Barrio ME, Martínez-Martínez I, de Cos C, Wypasek E, Roldán V, Undas A, et al. Hypoglycosylation is a common finding in antithrombin defi- ciency in the absence of a SERPINC1 gene defect. J Thromb Haemost. 2016 Aug;14(8):1549-60.
25. De la Morena-Barrio ME, Wypasek E, Owczarek D, Miñano A, Vicente V, Cor- ral J, Undas A. MPI-CDG with transient hypoglycosylation and antithrombin deficiency. Haematologica. 2019 Feb;104(2):e79-e82.
26. Ramanathan T, Hughes TM, Richardson AJ. Perinatal inferior vena cava throm- bosis and absence of the infrarenal inferior vena cava. J Vasc Surg. 2001 May;33(5):1097-9.
27. Kovac M, Mitic G, Djilas I, Kuzmanovic M, Serbic O, Lekovic D, et al. Genotype phenotype correlation in a pediatric population with antithrombin deficiency. Eur J Pediatr. 2019 Oct;178(10):1471-8.
28. Friedberg EC. Hot news: temperature-sensitive humans explain hereditary disease. Bioessays. 2001 Aug;23(8):671-3.
29. Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Hae- matologica. 2005 Feb;90(2):238-46.
30. Beauchamp NJ, Pike RN, Daly M, Butler L, Makris M, Dafforn TR, et al. Anti- thrombins Wibble and Wobble (T85M/K): archetypal conformational diseas- es with in vivo latent-transition, thrombosis, and heparin activation. Blood. 1998 Oct 15;92(8):2696-706.
31. Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, Miñano A, Bohdan N, Águila S,et al.Antithrombin Dublin (p.Val30Glu):a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost. 2016 Jul 4;116(1):146-54.
32. Bravo-Pérez C, Vicente V, Corral J. Management of antithrombin deficiency: an update for clinicians. Expert Rev Hematol. 2019 Jun;12(6):397-405.
 LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
 30























































   28   29   30   31   32